Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eculizumab for Prevention of Delayed Graft Function After Kidney Transplantation
2013-004650-25Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in delayed graft function (DGF) comparing Eculizumab with Placebo (2 arms). Primary endpoint: Incidence of delayed graft function. Started May 2014; status: completed.
02
Drugs
eculizumab
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on 2013-004650-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004650-25.